ArticleEuropean journal of heart failure2021

Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.

Claudio Rapezzi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.